As we've seen throughout the pandemic, Abbott's diverse business portfolio continues to be highly resilient, reflected by its strong third-quarter results. Based on the company's strong performance — including double-digit earnings and sales growth — and the company's outlook, Abbott raised its 2021 adjusted diluted earnings-per-share1 (EPS) guidance from continuing operations to $5.00 – 5.10,2 which reflects 38.4% growth at the midpoint compared to last year.3 Here are the key numbers: $10.9 billion in worldwide sales, up 22.4% organic* (23.4% reported) versus the third quarter of 2020. $1.40 adjusted diluted EPS, reflecting 42.9% growth compared to the prior year.4 Comparing these results to a pre-pandemic baseline illustrates the true strength of Abbott's businesses. Sales — excluding COVID-19 testing — grew double digits, 11.7% on both an organic and reported basis versus pre-pandemic levels in the third quarter of 2019. These are the key third-quarter highlights: Solid Medical Devices sales — 13.1% organic (14.6% reported) — spurred by continued recovery from the COVID-19 pandemic and strong growth in Diabetes Care. This growth was driven by sales of FreeStyle Libre systems and Libre Sense, $968 million in the quarter, which translates to an increase of 38.8% organic (41.6% reported). Robust growth in Diagnostics — 46.8% organic (48.2% reported) — with COVID-19 testing-related sales of $1.9 billion, of which approximately $1.6 billion were rapid tests. Excluding COVID-19 testing-related sales, global diagnostics sales increased 12.5% organic (14.1% reported). Strong Nutrition sales — up 8.9% organic (9.6% reported) — driven by international adult and U.S. pediatric Nutrition, with strong performance of Abbott's market-leading brands Ensure, Glucerna and Pedialyte. Highly productive pipeline — Several new products launched in large, high-growth markets, including Amplatzer Amulet, Portico with FlexNav TAVR system and the FreeStyle Libre 2 iOS app in the U.S. — and there's more expected. Abbott also expanded its Vascular portfolio with the acquisition of Walk Vascular, LLC, a commercial-stage medical device company with a minimally invasive thrombectomy system designed to remove peripheral blood clots. For full financials and reconciliation of non-GAAP measures, you can read Abbott's press release. For further information, take a look at some additional materials below: Abbott President and CEO Robert Ford summarizes the company’s third-quarter results and full-year outlook.